Evaluation of Pre-existing Antibody Presence as a Risk Factor for Posttreatment Anti-drug Antibody Induction: Analysis of Human Clinical Study Data for Multiple Biotherapeutics
- 13 June 2013
- journal article
- research article
- Published by Springer Science and Business Media LLC in The AAPS Journal
- Vol. 15 (3), 893-896
- https://doi.org/10.1208/s12248-013-9497-z
Abstract
No abstract availableKeywords
This publication has 8 references indexed in Scilit:
- Pre-Existing Biotherapeutic-Reactive Antibodies: Survey Results Within the American Association of Pharmaceutical ScientistsThe AAPS Journal, 2013
- Epitope characterization of pre-existing and developing antibodies to an aglycosylated monoclonal antibody therapeutic of G1m17,1 allotypeJournal of Immunological Methods, 2012
- Immunogenicity and Safety of Re-Exposure to Recombinant Human Thrombin in Surgical HemostasisJournal of the American College of Surgeons, 2011
- Immunogenicity of panitumumab in combination chemotherapy clinical trialsBMC Clinical Pharmacology, 2011
- High avidity cytokine autoantibodies in health and disease: Pathogenesis and mechanismsCytokine & Growth Factor Reviews, 2010
- Safety and Immunogenicity Observations Pooled from Eight Clinical Trials of Recombinant Human ThrombinJournal of the American College of Surgeons, 2010
- Cetuximab-Induced Anaphylaxis and IgE Specific for Galactose-α-1,3-GalactoseThe New England Journal of Medicine, 2008
- Preexisting Antibodies to Platelet Factor 4-Heparin Complexes in Patients with Acute Coronary Syndrome Who Have No History of Heparin ExposurePathophysiology of Haemostasis and Thrombosis, 2005